SAB Biotherapeutics, Inc.
SABS
$3.72
$0.082.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 107.02% | -191.12% | |||
| Gross Profit | -107.02% | 191.12% | |||
| SG&A Expenses | 35.59% | -12.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.28% | -9.65% | |||
| Operating Income | -30.28% | 9.65% | |||
| Income Before Tax | 549.32% | -94.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 549.32% | -94.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 549.32% | -94.63% | |||
| EBIT | -30.28% | 9.65% | |||
| EBITDA | -33.00% | 10.37% | |||
| EPS Basic | -33.16% | 233.94% | |||
| Normalized Basic EPS | 491.94% | -94.45% | |||
| EPS Diluted | -128.38% | 233.94% | |||
| Normalized Diluted EPS | 153.66% | -94.45% | |||
| Average Basic Shares Outstanding | 14.64% | 0.09% | |||
| Average Diluted Shares Outstanding | 737.28% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||